AstraZeneca

45 YEARS
Bringing science to patients since 1979

July 18, 2026

The Manager - Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400051

The Manager - Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai - 400001

Dear Sir/ Madam,

Sub: Notice of the 47th Annual General Meeting
Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of the 47th Annual General Meeting of the Company scheduled to be held on Monday, August 10, 2026 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM).

The Notice is being sent through electronic mode to those Members who have registered their email ID with the Company/ Depositories/Registrar and Share Transfer Agent of the Company. Further, in accordance with Regulation 36(1)(b) of the Listing Regulations, a physical communication containing the weblink for accessing the Notice of the AGM and Annual Report for the financial year ended March 31, 2026 is being sent to those Members whose email addresses are not registered.

The said Notice along with the Annual Report for the financial year ended March 31, 2026 is also available on the website of the Company at www.astrazeneca.com/india.

This is for your kind information and records.

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.07.18 16:28:29 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer
ACS No. 25784

Encl: as above

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited
Registered Office: Block N1, 12th Floor, Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road, Bangalore – 560 045
CIN: L24231KA1979PLC003563, **Web:** www.astrazeneca.com/india
E-mail: comp.secy@astrazeneca.com, Tel: +91 80 6774 8000

Notice

NOTICE is hereby given that the 47th Annual General Meeting of the Members of AstraZeneca Pharma India Limited will be held on Monday, August 10, 2026 at 3:00 PM through Video Conferencing ('VC')/Other Audio-Visual Means ('OAVM') to transact the following business:

ORDINARY BUSINESS

Item No. 1
To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon.

Item No. 2
To declare Dividend of Rs. 36/- per share on equity shares for the financial year 2025-26.

Item No. 3
To appoint a Director in place of Ms. Bhavana Agrawal (DIN: 10485441) who retires by rotation, and being eligible, offers herself for re-appointment.

SPECIAL BUSINESS

Item No. 4
Appointment of Statutory Auditors of the Company
To consider and if thought fit, to convey assent or dissent to the following Ordinary Resolution:

RESOLVED THAT pursuant to the provisions of Sections 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 including any statutory modification(s) or re-enactment thereof for the time being in force, the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, and based on the recommendation of the Audit Committee and the Board of Directors of the Company, M/s. BSR & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022), be and are hereby appointed as the Statutory Auditors of the Company to hold office for a term of 5 (five) consecutive years from the conclusion of this 47th Annual General Meeting till the conclusion of 52nd Annual General Meeting of the Company to be held in the calendar year 2031, at such remuneration as may be approved by the Board of Directors (which term shall include its duly empowered Committee(s)) from time to time.

RESOLVED FURTHER THAT the Board of Directors of the Company, be and are hereby authorized to do all such acts, deeds, matters and things and to take all such steps as may be required and to execute all documents, applications, returns and writings as may be necessary, proper, desirable or expedient to give effect to this resolution or for the matters connected therewith or incidental thereto."

Item No. 5
Re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director
To consider and if thought fit, to convey assent or dissent to the following Special Resolution:

RESOLVED THAT pursuant to the provisions of Sections 149, 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (the 'Act') read with the Companies (Appointment and Qualifications of Directors) Rules, 2014 and any other rules, circulars, notifications, etc. issued under the Act (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), Regulations 17, 25 and other applicable provisions, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including any amendment(s) thereto ('SEBI Listing Regulations'), and the Articles of Association of the Company, Ms. Shilpa Divekar Nirula (DIN: 06619353), who was appointed as an Independent Director of the Company for a period of five years with effect from December 29, 2021 and who holds office up to December 28, 2026 and who meets the criteria for independence as provided in Section 149(6) of the Act and the Rules made thereunder and Regulation 16(1)(b) of the SEBI Listing Regulations and in respect of whom the Company has received a notice in writing under Section 160 of the Act from a member proposing her candidature for the office of Director, being eligible, be and is hereby re-appointed as an Independent

Director, not liable to retire by rotation to hold office for a second term of 5 (five) consecutive years commencing from December 29, 2026 to December 28, 2031 (both days inclusive).

RESOLVED FURTHER THAT approval of the Members be and is hereby accorded to the Board of Directors (which term shall include its duly empowered Committee(s)) to do all such acts, deeds, matters and things and to take all such steps as may be required and to settle any questions, difficulties or doubts that may arise in this regard and further to execute all necessary documents, applications, returns and writings as may be necessary, proper, desirable or expedient to give effect to this resolution or for the matters connected therewith or incidental thereto.

By Order of the Board of Directors
For **AstraZeneca Pharma India Limited**

Tanya Sanish
Company Secretary
Membership No.: A25784

Place: Bengaluru
Date: May 26, 2026

Notes:

1) Pursuant to the Ministry of Corporate Affairs ('MCA') General Circular dated May 5, 2020 read with circulars dated April 8, 2020, April 13, 2020, and subsequent circulars issued in this regard, the latest one being circular no. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs (collectively referred to as 'MCA Circulars'), MCA has permitted the holding of the Annual General Meeting ('AGM') through VC/OAVM, without the physical presence of the members at a common venue. In compliance with the provisions of the Companies Act, 2013 ('the Act'), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations') and MCA Circulars, the AGM of the Company is being held through VC/OAVM.

2) This Notice is being sent to the Members whose names appear in the List of Beneficial Owners received from National Securities Depository Limited/ Central Depository Services (India) Limited ('Depositories'). In compliance with the aforesaid MCA Circulars and SEBI Circular(s) as may be applicable, Notice of the AGM along with the Annual Report 2025-26 is being sent only through electronic mode to those Members whose e-mail addresses are registered with the Company/ Depository Participants.

   Additionally, the Company will also send a letter providing the web-link for accessing the Annual Report to those Members who have not registered their email address with the Company or RTA or DP in compliance with the Regulation 36(1) of the Listing Regulations.

3) For members whose e-mail addresses are not registered but mobile numbers are registered with Integrated Registry Management Services Private Limited ('RTA')/Depositories, the weblink for downloading the Notice is being sent through SMS.

4) Members holding shares in demat mode who have not registered their e-mail address are required to update the same at their depository participant where they are have their account and Members holding shares in physical mode kindly send the KYC documents to the RTA address to register their e-mail id and KYC details. In case of any queries, Member may write to irg@integratedindia.in.

5) Members are also requested to register their e-mail address, in respect of electronic holdings with the Depositories/Depository Participant and in respect of physical holdings with the RTA.

6) Pursuant to the MCA Circulars, the facility to appoint proxy to attend and cast vote for the Members is not available for this AGM. However, Corporate Members are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and cast their votes through e-voting.

7) The facility of participation at the AGM through VC/OAVM will be made available for Members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

8) The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act.

9) Since the AGM will be held through VC/OAVM, the route map is not annexed to this Notice.

10) Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and

Regulation 44 of the Listing Regulations (as amended), and the MCA Circulars, the Company is providing the facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorised agency. The facility of casting votes by a member using remote e-voting system as well as on the date of the AGM will be provided by NSDL.

11) In line with the MCA Circulars, the Notice calling the AGM and the Annual Report for 2025-26 has been uploaded on the website of the Company at www.astrazeneca.com/india. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-voting facility) i.e. www.evoting.nsdl.com.

12) The Statement pursuant to Section 102 of the Act and the Listing Regulations, setting out the material facts concerning item no. 4 and 5 of the Notice, being Special Business, is annexed hereto.

13) Relevant documents referred to in the accompanying Notice calling the AGM, Register of Directors and Key Managerial Personnel and their Shareholding and the Register of Contracts or Arrangements in which the Directors are interested, maintained under the Act are available for inspection by the Members electronically during the 47th AGM. Members seeking to inspect such documents can send e-mail to comp.secy@astrazeneca.com.

14) Payment of dividend as recommended by the Board of Directors, if approved at the meeting, will be made to those Members whose names are on the Company's Register of Members on July 31, 2026 (record date) and those whose names appear as Beneficial Owners as at the close of business hours on July 31, 2026 as per the details furnished by the Depositories, viz. National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) for this purpose.

15) In accordance with the provisions of the Income Tax Act, 2025 as amended and read with applicable provisions of law, dividend declared and paid by the Company is taxable in the hands of its Members and the Company is required to deduct tax at source (TDS) from dividend paid to the Members at the applicable rates. A separate e-mail will be sent at the registered e-mail ID of the Members describing about the detailed process to submit the documents/declarations along with the formats in respect of deduction of tax at source on the dividend payout.

16) Members may please note that in line with relevant SEBI circulars, dividends shall be processed only in electronic mode. Payment through dividend warrants or cheques has been discontinued. Dividend payment shall be subject to:

    (a) For shares held in physical form: Folio being KYC compliant, i.e., PAN, contact details including mobile number, bank account details (including IFSC and MICR codes) and specimen signature are registered with the Company's Registrar and Transfer Agent ('RTA') by submitting Form ISR - 1.

    (b) For shares held in dematerialised form: Updation of bank account details with the respective Depository Participants viz. NSDL and CDSL.

17) Members may please note that SEBI vide its Circular No. SEBI/ HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, has mandated the listed companies to issue securities in dematerialised form only while processing service requests viz. issue of duplicate securities certificate; claim from unclaimed dividend account; exchange of securities certificate; subdivision of securities certificate; consolidation of securities certificates/folios; transmission and transposition. Members are requested to contact the RTA at irg@integratedregistry.in for the same.

18) SEBI vide its notification dated January 24, 2022 has mandated that all requests for transfer of securities including transmission and transposition requests shall be processed only in dematerialised form. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialisation, Members are advised to dematerialise the shares held by them in physical form. Members can contact the Company or the RTA, for assistance in this regard.

19) To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company of any change in address or demise of any member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned Depository Participant and holdings should be verified.

20) SEBI has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form

are, therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN details to the Company. Further, the Non-Resident Indian Members are requested to inform the RTA on change in their residential status on return to India for permanent settlement and particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with PIN Code, if not furnished earlier.

Members holding shares in dematerialised form are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/mobile number, PAN, mandates, nominations, bank details, etc. to their respective Depository Participants viz. NSDL and CDSL.

21) Members are requested to note that dividends not encashed or remaining unclaimed for a period of 7 (seven) years from the date of transfer to the Company's Unpaid Dividend Account, shall be transferred under Section 124 of the Act, to the Investor Education and Protection Fund (IEPF), established under Section 125 of the Act. Further, as required under the said Act/ Rules, the Shares that are unclaimed by members for seven consecutive years or more shall be transferred to the IEPF. The members/ claimants whose unclaimed dividends/shares have been transferred to IEPF may claim the shares or apply for refund by making an application to IEPF Authority in Form IEPF-5 (available on www.iepf.gov.in) along with requisite fee.

22) Details as required under the Listing Regulations and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India in respect of the Director seeking re-appointment at the AGM form an integral part of the Notice. The Directors have furnished requisite declarations for re-appointment as applicable.

23) The facility for making nomination is available for Members in respect of shares held by them. Members holding shares in physical form and who have not yet registered their nomination are requested to register the same by submitting Form SH-13 with the RTA. If a Member desires to opt out or cancel an earlier nomination and record a fresh nomination, the Member may submit the same in Form ISR-3 or Form SH-14, as the case may be. The said Forms can be downloaded from the website of the RTA at www.integratedregistry.in. Members holding shares in dematerialised form are requested to register/update their nomination details with their respective Depository Participants.

24) A special window, as per the mandate of SEBI, is available till February 4, 2027, to facilitate lodgement of transfer requests that were executed before April 1, 2019 but were either not lodged for transfer or were lodged and subsequently rejected, returned, or not attended due to deficiency in documents. Eligible shareholders are requested to submit the requisite documents before February 4, 2027, to the RTA. Securities transferred through this mechanism shall be credited only in dematerialised form and shall remain under a one-year lock-in period, during which they cannot be transferred, lien-marked, or pledged.

25) SEBI has made available an online dispute resolution mechanism through the SMART ODR Portal for investors to raise disputes arising in the Indian Securities Market. After exhausting options to resolve grievances directly with the Company/RTA and through the SCORES platform, investors may initiate dispute resolution through the SMART ODR Portal at https://smartodr.in.

26) For any further communication, the Members may also write to the Company's investor e-mail ID: comp.secy@astrazeneca.com.

27) Voting Through Electronic Means

In compliance with the provisions of Section 108 of the Act, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of the Listing Regulations, the Company is pleased to provide members facility to exercise their right to vote on resolutions proposed to be considered at the AGM by electronic means and the business may be transacted through e-voting services. The facility of casting the votes by the members using an electronic voting system ('remote e-voting') will be provided by NSDL

The instructions for e-voting are as under:

Step 1: Access to NSDL e-Voting system

A. Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and e-mail Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
	2. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period.
	3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp
	4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
	5. Shareholders can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR Code mentioned below for seamless voting experience **NSDL Mobile App is available on** App Store Google Play
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi/ Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password.
	2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.
	3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.
	4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & e-mail id as recorded in the demat Account. After successful authentication, user will be able to see the e-Voting option where the e-Voting is in progress and also able to directly access the system of all e-Voting Service Providers.

Type of shareholders	Login Method
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on Company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting and voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at 022 - 4886 7000.
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911.

B. Login Method for e-Voting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode:

(i) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.

(ii) Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.

(iii) A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

(iv) Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical		Your User ID is:
(a)	For Members who hold shares in demat account with NSDL	8 Character DP ID followed by 8 Digit Client ID For example, if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******
(b)	For Members who hold shares in demat account with CDSL	16 Digit Beneficiary ID For example, if your Beneficiary ID is 12************** then your user ID is 12**************
(c)	For Members holding shares in Physical Form	EVEN Number followed by Folio Number registered with the Company. For example, if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

(v) Your password details are given below:

(a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.

(b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

(c) How to retrieve your 'initial password'?

- If your e-mail ID is registered in your demat account or with the Company, your 'initial password' is communicated to you on your e-mail ID. Trace the e-mail sent to you from NSDL from your mailbox. Open the e-mail and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
- If your e-mail id is not registered, please follow steps mentioned below in process for those shareholders whose e-mail ids are not registered.

(vi) If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

(a) Click on 'Forgot User Details/Password?' (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.

(b) Click on 'Physical User Reset Password?' (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.

(c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address.

(d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

(vii) After entering your password, tick on Agree to 'Terms and Conditions' by selecting on the check box.

(viii) Now, you will have to click on 'Login' button.

(ix) After you click on the 'Login' button, Home page of e-Voting will open.

Step-2: Cast your vote electronically and join General Meeting on NSDL e-Voting System

(i) After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

(ii) Select 'EVEN' of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "JOIN GENERAL MEETING".

(iii) Now you are ready for e-Voting as the Voting page opens.

(iv) Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on 'Submit' and also 'Confirm' when prompted.

(v) Upon confirmation, the message 'Vote cast successfully' will be displayed.

(vi) You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

(vii) Once you confirm your vote on the resolutions, you will not be allowed to modify your vote.

C. Other instructions:

(i) Institutional members (other than Individuals, HUF, NRI, etc.) are also required to send a scanned copy (PDF/JPG format) of the relevant Board Resolution / Authority Letter, etc., together with an attested specimen signature of the duly authorised signatory(ies) who are authorised to vote, to the Scrutinizer through e-mail on vijaykt@vjkt.in with a copy marked to evoting@nsdl.co.in. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution /Authority Letter" displayed under "e-Voting" tab in their login.

(ii) It is strongly recommended that you do not share your new password and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the 'Forgot User Details/Password?' or 'Physical User Reset Password?' option available on www.evoting.nsdl.com to reset the password.

(iii) In case of any queries, you may refer to the Frequently Asked Questions (FAQs) for members and remote E-voting User Manual for members available at the 'Downloads' section of www.evoting.nsdl.com or send a request at evoting@nsdl.co.in. Any query or grievance connected with the remote e-voting may be addressed to Mr. Falguni Chakraborty, Deputy Manager, NSDL at 022-4886 7000.

(iv) You can also update your mobile number and e-mail ID in the user profile details of the folio which may be used for sending future communication(s).

(v) The remote e-Voting period commences on August 6, 2026 (9.00 a.m. IST) and ends on August 9, 2026 (5.00 p.m. IST) for four days. During this period, Members of the Company, holding shares either in physical form or in dematerialised form, as on the cut-off date August 3, 2026 may cast their vote through remote e-Voting.

(vi) The voting rights of Members shall be in proportion to their shares of the paid-up equity share capital of the Company as on the cut-off date of August 3, 2026.

(vii) Any person, who acquires shares of the Company and becomes member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. August 3, 2026, may obtain the login ID and password by sending a request at evoting@nsdl.co.in or irg@integratedregistry.in. However, if you are already registered with NSDL for remote e-voting, then you can use your existing user ID and password for casting your vote. If you have forgotten your password, you can reset your password by using 'Forgot User Details/Password' option available on www.evoting.nsdl.com or contact NSDL at 022 - 4886 7000.

(viii) A person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as voting at the AGM through e-voting. For the purpose of e-voting, a person who is not a Member as on cut-off date should treat this Notice for information purpose only.

(ix) **The instructions for members for e-voting on the day of the AGM are as under:-**

a. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

b. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not cast their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

c. Members who have voted through remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.

d. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for remote e-voting.

(x) The Board of Directors has appointed Mr. Vijayakrishna K.T., Practising Company Secretary, (Membership No. FCS 1788) as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner. He has conveyed to the Company his willingness to act as such.

The Scrutinizer shall, immediately after the conclusion of voting at the AGM, unblock the votes cast through remote e-voting (votes cast during the AGM and votes cast through remote e-voting) and will submit a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairperson or a person authorized by her in writing. The results will be announced within the time stipulated under the applicable laws.

(xi) The Results declared along with the Scrutinizer's Report shall be placed on the Company's website www.astrazeneca.com/india and on the website of NSDL, immediately after the result is declared by the Chairperson and communicated to the stock exchanges, where the equity shares of the Company are listed.

(xii) **Instructions for members for attending the AGM through VC/OAVM are as under:**

a. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access the same at https://www.evoting.nsdl.com under shareholders/members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

b. Facility of joining the AGM through VC/OAVM shall open 30 minutes before the time scheduled for the AGM and will be available for Members on first cum first served basis.

c. Members are encouraged to join the Meeting through Laptops for better experience.

d. Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

e. Please note that participants connecting from mobile devices or tablets or through laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

f. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker and send their request mentioning their name, demat account number/folio number, email id, mobile number and PAN at comp.secy@astrazeneca.com between 9.00 a.m. IST on August 2, 2026 and 5 p.m. IST on August 4, 2026.

g. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting. Members are requested to submit their questions at the times of registration, to enable the Company to respond appropriately.

h. The Company reserves the right to restrict the number of questions and number of speakers, depending upon availability of time as appropriate for smooth conduct of the AGM.

i. Members who need assistance before or during the AGM, can contact NSDL at evoting@nsdl.co.in or contact Mr. Falguni Chakraborty, Deputy Manager, NSDL at 022-4886 7000.

Process for those shareholders whose e-mail ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode, please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), Aadhaar (self-attested scanned copy of Aadhaar Card) by e-mail to irg@integratedregistry.in.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), Aadhaar (self attested scanned copy of Aadhaar Card) to irg@integratedregistry.in. If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting for Individual shareholder holding securities in demat mode.

3. Alternatively, shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories. Shareholders are required to update their mobile number and e-mail ID correctly in their demat account in order to access e-Voting facility.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013 ('Act') AND SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ('Listing Regulations')

Item No. 4

Appointment of Statutory Auditors of the Company

Pursuant to Section 139 of the Act and Rules made thereunder, it is mandatory to rotate a firm of Statutory Auditors on completion of two terms of five consecutive years. M/s. Price Waterhouse and Co. Chartered Accountants LLP (Firm Registration No. 304026E/E-300009) will have served as Statutory Auditors for two consecutive terms aggregating to ten years upon conclusion of the ensuing Annual General Meeting ('AGM'). Further, based on the recommendation of the Audit Committee at its meeting held on May 26, 2026, the Board has approved and recommended to the Members, the appointment of M/s. BSR & Co. LLP, Chartered Accountants, (Firm Registration No. 101248W/W-100022) as the Statutory Auditors of the Company in place of M/s. Price Waterhouse and Co. Chartered Accountants LLP ('Retiring Auditors').

It is proposed that M/s. BSR & Co. LLP will hold office for a period of five consecutive years from the conclusion of the 47th Annual General Meeting of the Company till the conclusion of the 52nd Annual General Meeting. The appointment is subject to the approval of the members of the Company. The Audit Committee and the Board of Directors considered various factors in recommending the appointment of M/s. BSR & Co. LLP as the Statutory Auditors of the Company such as reputation and track record, industry experience, independence and audit approach, ability to understand the Company's operations, systems and processes, use of technologies and methods to advance audit quality, and considered it to be suitable for appointment as Statutory Auditors.

M/s. BSR & Co. LLP was constituted on March 27, 1990 as a partnership firm and was thereafter converted into limited liability partnership on October 14, 2013. The registration no. of the firm is 101248W/W-100022. M/s. BSR & Co. LLP is a member entity of BSR & Affiliates, a network registered with the Institute of Chartered Accountants of India ('ICAI'). The firm has over 4,000 staff and 170+ Partners and has offices across 14 locations. The firm audits various companies listed on the Stock Exchanges in India including companies in the pharmaceuticals sector.

M/s. BSR & Co. LLP has consented to their appointment as Statutory Auditors and have confirmed that their appointment, if made, shall be in compliance with Sections 139 and 141 of the Act and Companies (Audit and Auditors) Rules, 2014 and that they have subjected themselves to the peer review process of the Institute of Chartered Accountants of India ('ICAI') and hold a valid certificate issued by the 'Peer Review Board' of the ICAI.

A fee of an amount not exceeding ₹ 80 lakhs towards audit of standalone financial statements and other audit engagements of the Company, excluding taxes and reimbursement of out-of-pocket expenses, is recommended for FY 2026-27. The remuneration for the subsequent period of their term shall be fixed by the Board of Directors on the recommendation of the Audit Committee.

The proposed remuneration to the incoming Statutory Auditors is commensurate with the scope, resources, and first-year transition requirements of the engagement.

None of the Director or Key Managerial Personnel or their relatives, is concerned or interested in this resolution, financially or otherwise.

The Board recommends the Ordinary Resolution set out at Item No. 4 of this Notice for approval of the Members.

Item No. 5

Re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director

Ms. Shilpa Divekar Nirula (DIN: 06619353) was appointed as an Independent Director of the Company pursuant to the provisions of Section 149 of the Act, read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and Regulations 17, 25 as well as other applicable provisions, if any, of the Listing Regulations, at the AGM of the Company held on August 8, 2022, to hold office from December 29, 2021 up to December 28, 2026. Further, Ms. Nirula serves as the Chairperson of the Board and is a Member of the Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee of the Board of Directors of the Company.

Ms. Nirula is an accomplished professional with over 28 years of experience, starting in consulting and successfully transitioning to the agriculture and food sector. She has worked for reputed organizations including Arthur Andersen, KPMG, Bunge Agribusiness, Monsanto and Bayer CropScience in roles of growing responsibility. At Bayer CropScience, Shilpa led Strategy and Commercial Excellence for the Asia-Pacific region and co-led the Global Smallholder Strategy between 2018 and 2020. She was the

CEO and MD of Monsanto India from 2014 to 2018. Prior to her over 12 years stint at Bayer and Monsanto, she was the Head of Strategy & Business Development for Bunge India, a US headquartered multinational involved in oilseeds, commodity trading & foods.

Since April 2020, Ms. Nirula has been mentoring businesses to help them turn around, grow, or start-up. She also holds an Independent Director position in other companies and is an advisor to Omnivore, an agri-tech focused venture capital fund. Ms. Nirula has recently co-founded AGVAYA LLP, a consulting and advisory services firm committed to assist participants across the agriculture and food value chains.

She is a post-graduate in Commerce, a Cost Accountant, Chartered Accountant and an MBA, started her career in 1996 at Arthur Andersen and KPMG and gained significant experience serving clients in diverse industry sectors.

The Company has received notice in writing pursuant to Section 160 of the Act, from a Member proposing the re-appointment of Ms. Nirula for the office of Independent Director. Further, Ms. Nirula is qualified to be appointed as a Director in terms of Section 164 of the Act and has given her consent to act as a Director along with other disclosures and declarations as required under the Act. The Company has also received a declaration from Ms. Nirula that she meets the criteria of independence as prescribed, both, under Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations and that she is not debarred from holding the office of director by virtue of any order passed by the Securities and Exchange Board of India / Ministry of Corporate Affairs or any such statutory authority. In the opinion of the Board, Ms. Nirula is a person of integrity and fulfils the conditions for appointment as an Independent Director as specified in the Act and Listing Regulations and is independent of the Management of the Company. While considering her re-appointment, the Board, pursuant to the recommendation of the Nomination and Remuneration Committee, took into account Ms. Nirula's skills, expertise, experience, independence and the contributions made by her during her first term in the Company including her role as the Chairperson of the Board and role on the various Committees of the Board, as well as her performance evaluation. Based on these factors, the Board is of the opinion that the continued association of Ms. Nirula as Independent Director of the Company would be of immense benefit to the Company and accordingly the Board has approved the re-appointment of Ms. Nirula as Independent Director, not liable to retire by rotation, to hold office for a second term of 5 (five) consecutive years from December 29, 2026 to December 28, 2031 (both days inclusive), subject to approval of the shareholders of the Company. Draft letter of appointment of Ms. Nirula, is available for inspection through electronic mode. Members seeking to inspect the same may do so by sending an email to comp.secy@astrazeneca.com. Also, an electronic copy of the terms and conditions of appointment of Independent Directors is available on the website of the Company at www.astrazeneca.com/india. Details required under Regulation 36(3) of the SEBI Listing Regulations and other provisions of applicable laws as well as the Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India ('SS- 2') are annexed as an Annexure to the Explanatory Statement. Except for Ms. Nirula and her relatives to the extent of their shareholding interest, if any, in the Company, none of the other Directors/ Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise, in this resolution.

The Board recommends the Special Resolution set out at Item No. 5 of this Notice for approval of the Members.

Annexure - I to Notice

Additional information on Directors recommended for appointment/re-appointment as required under Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards on General Meetings:

Name of the Director	Ms. Bhavana Agrawal (DIN: 10485441)	Ms. Shilpa Divekar Nirula (DIN: 06619353)
Age (years)	47	52
Nationality	Indian	Indian
Date of first Appointment	February 8, 2024	December 29, 2021
Qualification(s)	Bachelor's degree in business studies from Delhi University and a Chartered Accountant.	Post-graduate in Commerce, a Cost Accountant, Chartered Accountant and an MBA
Brief profile and nature of their expertise in specific functional areas	Ms. Bhavana Agrawal is currently the Chief Financial Officer of AstraZeneca Pharma India Limited. She has over two decades of finance experience and has worked across multiple geographies & businesses. She played various roles with GE prior to joining AstraZeneca and her last responsibility was based out of Dubai as a CFO - Services business at GE Healthcare for Middle East, Africa & Russia where she provided Finance leadership to $300M revenue business across 30+ countries. With her expertise around Commercial Finance, P&L Management, financial planning / Analysis, Cash flow management, Accounting & Controls, she was a strategic finance partner for businesses with consistent performance in maximising revenue, margin and cash. She carries strong leadership with proven record in creating positive team culture and growth. Prior to CFO role, she had undertaken multiple roles across finance domain between 2003 to 2015 in Dubai and India for GE. Ms. Bhavana Agrawal is an All-India rank holder Chartered Accountant.	Ms. Shilpa Divekar Nirula has worked for reputed organizations including Arthur Andersen, KPMG, Bunge Agribusiness, Monsanto and Bayer CropScience in roles of growing responsibility. At Bayer CropScience, Shilpa led Strategy and Commercial Excellence for the Asia-Pacific region and co-led the Global Smallholder Strategy between 2018 and 2020. Shilpa was the CEO and MD of Monsanto India from 2014 to 2018. Prior to her over 12 years stint at Bayer and Monsanto, she was the Head of Strategy & Business Development for Bunge India, a US headquartered multinational involved in oilseeds, commodity trading & foods. Since April 2020, Ms. Nirula has been mentoring businesses to help them turn around, grow, or start-up. She also holds an Independent Director position in other listed companies and is an advisor to Omnivore, an agri-tech focused venture capital fund. Ms. Nirula has recently co-founded AGVAYA LLP, a consulting and advisory services firm committed to assist participants across the agriculture and food value chains.
Terms and conditions of Appointment/ Reappointment including remuneration sought to be paid	Eligible to retire by rotation and remuneration as recommended by the Nomination & Remuneration Committee and approved by the Board from time to time.	As recommended by the Nomination & Remuneration Committee and approved by the Board of Directors for sitting fees as permitted under the Companies Act, 2013
Remuneration last drawn	Remuneration last drawn is furnished in the Corporate Governance Report of the Company, which forms an integral part of this Annual Report	Remuneration last drawn is furnished in the Corporate Governance Report of the Company, which forms an integral part of this Annual Report
Number of Meetings of Board attended during the year 2025-26	6	5
Directorships held in other companies (excluding Section 8 and foreign companies under the Act)	None	- GMM Pfaudler Limited - Clean Max Enviro Energy Solutions Limited - Kreditserve Financial Advisory Services Private Limited - Grow Indigo Private Limited

Name of the Director	Ms. Bhavana Agrawal (DIN: 10485441)	Ms. Shilpa Divekar Nirula (DIN: 06619353)
Membership/ Chairmanships of Committees of other companies (Statutory Committees)	None	GMM Pfaudler Limited: - Chairperson of Audit Committee - Member of Nomination and Remuneration Committee
Listed companies from which ceased to be a director in the past 3 years	Not applicable	None
Shareholding in the Company (No. of shares)	Nil	Nil
Relationship between Directors, inter-se	None	None

By Order of the Board of Directors

For **AstraZeneca Pharma India Limited**

Tanya Sanish

Company Secretary

Membership No.: A25784

Place: Bengaluru

Date: May 26, 2026